Applied Clinical Education

Managing Recurrent Clostridioides Difficile Infection:
Advancing the Science of Microbiome-Based Therapies

1.5 AMA PRA Category 1 Credits™
1.5 Accreditation Council for Pharmacy Education contact hours

Educational Objectives
After completing the activity, clinicians should be able to:
🎯Recognize the substantial health burdens associated with rCDI.
🎯Describe the pathogenesis of rCDI, including the role of alterations in the intestinal microbiota.
🎯Discuss the benefits and risks of antimicrobial treatment approaches for rCDI
🎯Evaluate the most up-to-date clinical trial data for new and emerging microbiota-restoration therapies for rCDI treatment.
Please visit CMEZone for activity at www.cmezone.com/MM233

Optimizing Early Detection of Nonalcoholic Steatohepatitis: A Patient-Centered Initiative

Target Audience
This activity is designed for general practitioners and other non-liver specialist clinicians involved in the early identification and diagnosis of NASH in at-risk populations.

Educational Objectives
After completing this activity, the participant should be better able to:
**Describe key risks for the development of NASH.
**Select appropriate noninvasive diagnostic tests to stratify risk in patients with NASH.
**Identify current guidance-recommended strategies for screening, evaluation, and referral of patients with NASH.
**Discuss health disparities that continue to affect underserved populations living with NASH.
**Review individualized care plans involving education, support, and empowerment for patients with NASH.
www.cmezone.com/MM237

New and Emerging Small Molecules: Making a Difference in UC
Target Audience

This educational activity is intended for gastroenterologists, gastroenterology physician assistants, and nurse practitioners involved in the care of patients with ulcerative colitis.

Learning Objectives
After completing this activity, participants will be better able to:
1. Review the mechanisms of action of small molecules for ulcerative colitis
2. Describe features of oral small molecules for ulcerative colitis
3. Summarize clinical evidence on small molecule drugs for ulcerative colitis
4. Identify patients who would be good candidates for treatment with small molecule drugs
www.cmezone.com/MM232

Optimizing Early Detection of Nonalcoholic Steatohepatitis: A Patient-Centered Initiative

Target Audience
This activity is designed for general practitioners and other non-liver specialist clinicians involved in the early identification and diagnosis of NASH in at-risk populations.

Educational Objectives
After completing this activity, the participant should be better able to:

**Describe key risks for the development of NASH.
**Select appropriate noninvasive diagnostic tests to stratify risk in patients with NASH.
**Identify current guidance-recommended strategies for screening, evaluation, and referral of patients with NASH.
**Discuss health disparities that continue to affect underserved populations living with NASH.
**Review individualized care plans involving education, support, and empowerment for patients with NASH.

www.cmezone.com/MM237

New and Emerging Small Molecules: Making a Difference in UC

Target Audience
This educational activity is intended for gastroenterologists, gastroenterology physician assistants, and nurse practitioners involved in the care of patients with ulcerative colitis.

Learning Objectives
After completing this activity, participants will be better able to:
1. Review the mechanisms of action of small molecules for ulcerative colitis
2. Describe features of oral small molecules for ulcerative colitis
3. Summarize clinical evidence on small molecule drugs for ulcerative colitis
4. Identify patients who would be good candidates for treatment with small molecule drugs
www.cmezone.com/MM232

Managing Recurrent Clostridioides Difficile Infection:
Advancing the Science of Microbiome-Based Therapies

1.5 AMA PRA Category 1 Credits™
1.5 Accreditation Council for Pharmacy Education contact hours

Educational Objectives
After completing the activity, clinicians should be able to:

🎯Recognize the substantial health burdens associated with rCDI.
🎯Describe the pathogenesis of rCDI, including the role of alterations in the intestinal microbiota.
🎯Discuss the benefits and risks of antimicrobial treatment approaches for rCDI
🎯Evaluate the most up-to-date clinical trial data for new and emerging microbiota-restoration therapies for rCDI treatment.

Please visit CMEZone for activity at www.cmezone.com/MM233

Managing Variants of COVID-19

ACTIVITY EXPIRES ON JANUARY 6TH

In light of the ever-changing data surrounding the continued emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, the understanding of the spectrum of COVID-19 and optimal management continues to develop, challenging healthcare professionals to stay abreast of the most current information with the potential to affect clinical decision-making. To mitigate the overall health burden associated with this devastating pandemic, providers must have current knowledge of the latest practice-changing information about recommended therapeutic and preventive strategies in the context of evolving variants that have varying effects on COVID-19 vaccines and therapeutics.

Take Activity The educational design of this activity addresses the needs of primary care providers, infectious disease clinicians, pulmonologists, critical care specialists, emergency physicians, health-system and specialty pharmacists, and other clinicians involved in the management of patients with coronavirus...